Pauline McGowan

Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA.

Stifel, Nicolaus & Co., Inc. (Stifel) is a dual-registered broker-dealer and investment adviser headquartered in St. Louis, Missouri. Founded in 1890, the firm is a subsidiary of Stifel Financial Corp. (NYSE: SF), a financial service holding company. Stifel provides full-service brokerage and investment advisory services to individuals and their families, institutions and businesses, and financial advisors.

SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA.

The World Economic Forum USA, Inc. operates an organization for economic reforms. The non-profit company is based in New York, NY.

Cambridge Medical & Rehabilitation Centre provides healthcare, rehab, and admission services. It provides individualized non-acute long-term care and therapies to patients who need post-hospital medical and rehabilitative treatment at intermediate or intensive levels of care. The firm also offers individualized non-acute medical, nursing, rehabilitation and social services to treat and support each of its residents, including a range of rehabilitation programs for residents who recover from an injury or illness. The company was founded in 2012 and is headquartered in Abu Dhabi, United Arab Emirates.

Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Part of Bourn Bioscience Ltd., Bourn Hall International Ltd. provides management services. The company is based in Limassol, Cyprus. Founded in 2009.

Manzil Health Care Services LLC provides home care services for adult and pediatric patients. It offers nursing care services, medical care and supporting medical care services and rehabilitation on intermediate and intensive level. The company was founded by Ghuwaya Al-Neyadi in 2011 and is headquartered in Abu Dhabi, United Arab Emirates.

F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.

Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

Bourn Hall LLC offers fertility treatment programs. It offers assisted reproductive technology, genetic testing and gender balancing, men's health, gynecology surgeries, fertility preservation, cosmetic gynecology, female fertility treatments, male fertility treatments, and Platelet Rich Plasma. The company was founded in 2012 and is headquartered in Dubai, the United Arab Emirates.

F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.

Tvm Capital Healthcare Partners Pte Ltd. operates as a healthcare private equity investor. The company is headquartered in Singapore.

The BioExec Institute, Inc. is a network of executives in the life sciences industry. The private company is based in Cambridge, MA. The company was founded in 2004 by Hoda Jeanne Abou-Jamra. Hoda Jeanne Abou-Jamra has been the CEO since 2004.

Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann.

ProVita International Medical Center LLC provides health care services. It offers continued care services such as rehabilitative therapies, social and cultural development, social and cultural integration. The company was founded by Christina Shawky on 2011 and is headquartered in Abu Dhabi, the United Arab Emirates.